VALUE Trial: Losartan for Coarctation of Aorta and High Blood Pressure
This study, called the VALUE Trial, is looking into how well Losartan works for people who have had surgery for coarctation of the aorta (a narrowing of the large artery that carries blood from the heart) and also have high blood pressure. Researchers want to see if Losartan can help improve the heart's structure. You might be able to join if you are 18 or older, have high blood pressure, and previously had coarctation of the aorta repaired. You cannot join if you are pregnant, breastfeeding, have certain kidney or heart conditions, or are already taking a beta blocker. The study will measure changes in heart scarring (Left Ventricular Fibrosis) after 52 weeks. The study is currently unclear about its recruitment status and plans to enroll 120 participants.
- Study design
- This interventional study will involve 120 participants. Participants will receive either Losartan, Amlodipine, or a placebo (a pill with no active drug) for 52 weeks.
- What's involved
- Participants will take a study drug orally once daily for 52 weeks. Measurements of Left Ventricular Fibrosis will be taken at the beginning and end of the study.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for 52 weeks, with the primary endpoint measured at that time.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial)
At a glance
Conditions
NCT06150560
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Mayo Clinic in Rochester
Rochester, Minnesotastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Alexander Egbe, MBBS, MPH · PRINCIPAL_INVESTIGATOR · Mayo Clinic
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Change in Left Ventricular (LV) FibrosisBaseline; Week 52
LV fibrosis will be measured via indexed Extracellular Volume (iECV) which will be calculated as extracellular volume fraction (ECV%) x LV End Diastolic Volume Index as evaluated during Cardiac Magnetic Resonance Imaging (CMRI).